CD44 and pachyonychia congenita: These results were corroborated with the suppression of recovering prostate cancer stem-like cells (CD44+/α1β2hi/CD133+) from high-grade primary PC, as well as the prevention of human CRPC tumor growth in mice via inhibition of either IL-6 or STAT3 [114].